The company said total GAAP revenues for Q1 2025 were $1,052,898 thousand, up 20% from $880,889 thousand a year earlier, and total net product revenues were $922,274 thousand, up 26%.

1. 01

   The company said total GAAP revenues for Q1 2025 were $1,052,898 thousand, up 20% from $880,889 thousand a year earlier, and total net product revenues were $922,274 thousand, up 26%.

2. 02

   Incyte said Jakafi net product revenues for Q1 2025 were $709 million (up +24% Y/Y), and it raised its full-year Jakafi guidance to $2,950 - $3,000 million from the prior $2,925 - $2,975 million.

3. 03

   The company said GAAP operating income for Q1 2025 was $205,168 thousand, up from $91,898 thousand a year earlier, while GAAP net income was $158,203 thousand, down from $169,548 thousand a year earlier.

4. 04

   The company said both Phase 3 studies of povorcitinib in HS (STOP-HS1, STOP-HS2) met the primary endpoint of HiSCR at Week 12 and at 1 tested doses. It also said cash, cash equivalents and marketable securities were $2.4 billion as of March 31, 2025.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.